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Mice null for Fyn (a member of the Src family
of nonreceptor tyrosine kinases) display a re-
duced percentage of adipose mass associated
with decreased adipocyte cell size. In parallel,
there is a substantial reduction in fasting plasma
glucose, insulin, triglycerides, and free fatty
acids concomitant with decreased intrahepato-
cellular and intramyocellular lipid accumulation.
Importantly, the Fyn null mice exhibit improved
glucose tolerance resulting from increased
peripheral tissue (adipose and skeletal muscle)
insulin sensitivity with a very small effect in the
liver. Moreover, whole-body, adipose, and skel-
etal muscle fatty acid uptake and oxidation are
increased alongwith AMP kinase activation and
acetyl-CoA carboxylase inhibition. Together,
these data demonstrate crosstalk between Src-
family kinase activity and fatty acid oxidation
and show that the loss of Fyn markedly im-
proves peripheral tissue insulin sensitivity by
relievingaselectivenegativemodulationofAMP
kinase activity in adipose tissue and skeletal
muscle.
INTRODUCTION
The members of the Src family of nonreceptor tyrosine
kinases share a conserved structure consisting of consec-
utive SH1, SH2, and SH3 domains. The catalytic tyrosine
kinase domain SH1 undergoes autophosphorylation,
and the SH2 domain binds a phosphorylated tyrosine res-
idue in the carboxy-terminal tail, stabilizing the structure
into an inactive conformation (Sicheri and Kuriyan,
1997). Phosphorylation of the inhibitory carboxy-terminal
site of the Src kinase is catalyzed by carboxy-terminalSrc kinase (CSK) and CSK-homologous kinase (CHK),
whereas several tyrosine phosphatases have been found
to dephosphorylate this site (Chong et al., 2005; Roskoski,
2005). The SH3 domain of the Src family members asso-
ciates with various targets through proline-rich motifs
responsible for substrate recognition and targeting. In
addition, the subfamily consisting of the Fyn, Src, and
Lyn kinases contains an amino-terminal SH4 domain,
which undergoes posttranslational dual acylation that, in
part, targets these kinases to lipid raft microdomains of
the plasma membrane (Dykstra et al., 2003; Liang et al.,
2001; van’t Hof and Resh, 1997, 1999). In addition, Fyn
has been reported to directly interact with two other lipid
raft-associated proteins, flotillin and CD36 (Bull et al.,
1994; Huang et al., 1991; Liu et al., 2005). In this regard,
several studies have also implicated Fyn in the regulation
of insulin action (Liu et al., 2005; Saltiel and Pessin, 2003).
For example, Fyn has been observed to directly associate
with insulin-stimulated tyrosine-phosphorylated IRS and
c-Cbl proteins (Myers et al., 1996; Ribon et al., 1998;
Sun et al., 1996). Fyn has been reported to be the kinase
responsible for 3T3-L1 adipocyte insulin-stimulated
caveolin tyrosine phosphorylation (Mastick and Saltiel,
1997). Moreover, pharmacological inhibition of Fyn kinase
activity was recently found to inhibit 3T3-L1 adipogenesis
(Sun et al., 2005).
Despite the apparent close relationship between insulin
signaling, lipid raft organization, and Fyn function in cul-
tured adipocytes, the in vivo role of Fyn in the regulation
of insulin biological responsiveness and/or metabolic
regulation has not been examined. To address this issue,
we have undertaken a systemic investigation of the meta-
bolic phenotype of Fyn null mice. We have observed that
in adipose tissue and skeletal muscle, Fyn induces a tonic
suppression of fatty acid oxidation through inhibition of
AMP kinase activity that is derepressed in Fyn null mice.
These data further demonstrate a critical metabolic cou-
pling between Fyn signaling and insulin action, regulating
peripheral tissue glucose homeostasis via modulation of
peripheral tissue fatty acid oxidation.Cell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc. 371
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Fyn Null Mice Display Increased Lipid OxidationFigure 1. Fyn Null Mice Display a Marked Reduction in Adiposity
(A) Growth curves of Fyn null (Fyn/) (n = 8) and wild-type (WT) (n = 9) mice on a chow diet. *p < 0.005. In this and all other figures, error bars represent
±SEM.
(B) Weights of white adipose tissue (WAT), liver, soleus, gastrocnemius, and heart normalized to body weight (n = 7 for Fyn null; n = 6 for WT).
(C) Visualization of total body fat in Fyn null and wild-type mice by microcomputed tomography. Positive and negative images are shown, with the
arrows pointing to subcutaneous and arrowheads pointing to visceral adipose tissue. Scale bar = 2 mm.
(D) Quantification of adipose tissue mass.
(E) Histological analysis of epididymal WAT. Magnification 203.RESULTS
Fyn Null Mice Display Reduced Adiposity
and Increased Glucose Clearance
Our initial observations of the Fyn null mice revealed a
reduced body weight at birth, with a reduction in the rate
of weight gain compared to control wild-type mice (Fig-
ure 1A) despite an identical food intake when normalized
to body mass (data not shown). At adult age (12 weeks),
the Fyn null mice had approximately 20% less body
mass than the wild-type mice due to a proportional reduc-
tion in all organs. However, when normalized to the total
body mass, no difference for liver, heart, soleus, and gas-
trocnemius muscles was observed between the two
strains (Figure 1B). Microcomputed tomography (micro-
CT) revealed that the total fat volume in the abdominal
area (from hips to ribs, excluding the lungs) was de-
creased by 55% (Figures 1C and 1D). When the fat volume
was normalized to the total tissue volume for each mouse372 Cell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc(Fyn null animals had, on average, a 34% smaller tissue
volume), Fyn null mice showed 32% lower fat-to-total tis-
sue ratio (data not shown). In particular, epididymal white
adipose tissue (WAT) was dramatically reduced in the Fyn
null mice (by 70%) compared to the wild-type (Fig-
ure 1B). The marked decrease in adipose tissue mass
was due to an approximate 60% reduction in adipocyte
cell size, with no significant alteration in adipocyte cell
number (Figure 1E).
The Fyn null mice also displayed an approximately 30%
and 60%decrease in fasting glucose and insulin levels, re-
spectively, compared to control mice (Figure 2A). Plasma
and intratissue triglycerides (TG) and nonesterified fatty
acid (NEFA) were also decreased in the Fyn null animals
compared to the control mice (Figure 2B and Table 1).
Since the Fyn null adipocytes also had reduced accumu-
lation of TG and NEFA coupled with a reduction in cell
size, the decrease in liver and skeletal muscle lipid content
was not a result of improved fat storage in the adipose.
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Fyn Null Mice Display Increased Lipid OxidationFigure 2. Fyn Null Mice Exhibit Improved
Lipid and Glucose Levels
(A) Fasting plasma glucose and insulin were
determined in wild-type (WT) and Fyn null
(Fyn/) mice. (n = 7 for Fyn null; n = 8 for WT.)
(B) Triglycerides (TG) and nonesterified fatty
acids (FFA) in Fyn null and WT mice after an
overnight fast. (n = 7 for Fyn null; n = 8 for WT.)
(C) Two-month-old wild-type control (filled cir-
cles) and Fyn null (open squares) mice were
fasted overnight and subjected to intraperito-
neal glucose-tolerance test. Two-month-old
Fyn null mice were injected with glucose
(1.2 g/kg) comparable to the 2-month-old
wild-type control mice (1 g/kg), resulting in
the identical total moles of injected glucose
per mouse (open triangles). Blood glucose
was measured before and 10, 20, 30, 45, 60,
90, 120, and 150 min after glucose adminis-
tration. (n = 7 for Fyn null; n = 6 for WT.)
(D) The glucose-tolerance test results for the
2-month-old control mice (23.0 ± 0.4 g) are
replotted for comparison with 4-month-old
(21.7 ± 0.3 g) and 7-month-old (23.7 ± 0.8 g)
Fyn null mice. (n = 5 for 4-month-old and
n = 2 for 7-month-old Fyn null mice.)
(E) Intraperitoneal glucose-tolerance test
results for control mice (WT, filled circles)
(25.0 ± 0.1 g) and mice heterozygous (Fyn+/,
open triangles) (23.8 ± 0.7 g) and homozygous
(Fyn/, open circles) (20.4 ± 0.8 g) for Fyn.
Animals were fasted for 16 hr, and glucose
(1 g/kg) was injected. Blood glucose level
was evaluated at the indicated time point.
(n = 3 for WT; n = 4 for Fyn/; n = 3 for Fyn+/.)
(F) Plasma insulin levels of age-matched
(2-month-old) animals were determined before
glucose injection and 30 and 60min after injec-
tion. (n = 7 for Fyn null; n = 6 for WT.)tissue. It is well established that intratissue TG and NEFA
can induce states of insulin resistance (Biddinger and
Kahn, 2006; Kelley et al., 2002; Krssak and Roden,
2004), and the reduced lipid content in the Fyn null mice
correlated with a marked increase in glucose tolerance
as shown during glucose-tolerance tests on age-matched
control and Fyn null mice (Figure 2C, compare filled circles
and open squares). Similarly, when injected with an iden-
tical total amount of glucose (that is, Fyn null mice re-
ceived 20% more glucose than the control mice based
upon their lean body mass), the Fyn null animals still dis-
played markedly improved glucose tolerance (Figure 2C,
compare filled circles and open triangles). As the Fyn
null mice have reduced total body mass compared to
age-matched control mice, we next weight-matched the
Fyn null mice by performing glucose-tolerance test com-
parisons between 2-month-old control wild-type (23.0 ±
0.4 g) mice and 4-month-old (21.7 ± 0.3 g) and 7-month-
old (23.7 ± 0.8 g) Fyn null mice. Although the 7-month-
old Fyn null mice had essentially identical body mass in
comparison with the younger control mice, they still dis-
played a greater glucose clearance (Figure 2D, compare
open and filled circles). Similarly, Fyn heterozygous ani-Cmals (Fyn+/) had only a 5% reduction in body weight
compared to control mice but still displayed improved
glucose clearance compared to control mice, albeit to
a lesser extent than the Fyn null (Fyn/) mice (Figure 2E).
These data are consistent with Fyn functioning in a
gene-dosage-dependent manner. The improved glucose
tolerance was not due to alterations in pancreatic b
cell function, as insulin secretion during the glucose
challenge in the 2-month-old Fyn null mice was lower
than but paralleled that of the 2-month-old wild-type
mice (Figure 2F).
Insulin Sensitivity Is Increased in Fyn Null Animals
To directly determine whether the enhanced glucose
tolerance was due to increased liver or peripheral tis-
sue insulin sensitivity, we next performed conscious
euglycemic-hyperinsulinemic (EU) clamps, coupled with
[3H]glucose infusion to assess liver glucose turnover.
[14C]2-deoxyglucose was injected as a bolus at the end
of the clamp to determine tissue-specific glucose trans-
port. As previously observed, following an overnight fast,
the Fyn null mice were hypoglycemic, with 2- to 3-fold
lower insulin levels. Glucose infusion rate, a measure ofell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc. 373
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Fyn Null Mice Display Increased Lipid Oxidationwhole-body insulin sensitivity, was increased by 40% in
the Fyn null mice relative to the control mice (Figure 3A).
Skeletal muscle glucose uptake measured at the end of
the EU clamp was elevated (50%) in the Fyn null mice
(Figure 3B). Remarkably, WAT glucose uptake was sub-
stantially increased (3-fold) in the Fyn null mice (Fig-
Table 1. Tissue-Associated Triglycerides and Fatty
Acids in White Adipose Tissue, Liver, Gastrocnemius,
and Soleus Skeletal Muscle
WT Fyn/
Triglyceride
WAT (mg/mg) 26.7 ± 0.8 7.95 ± 1.1*
Liver (mg/mg) 371 ± 22 140 ± 8.6*
Gastroc. (mg/mg) 192 ± 24 60.7 ± 5.5*
Soleus (mg/mg) 68.4 ± 6.7 32.4 ± 4.6*
NEFA
WAT (mg/mg) 2.12 ± 1.0 0.53 ± 0.1*
Liver (mg/mg) 24.9 ± 1.5 10.1 ± 1.5*
Gastroc. (mg/mg) 8.54 ± 0.2 3.37 ± 0.3*
Soleus (mg/mg) 3.68 ± 1.0 1.25 ± 0.2*
Fasted 3-month-old control (WT) and Fyn null (Fyn/) mice
were sacrificed, and tissue-associated triglyceride and non-
esterified fatty acid (NEFA) levels were determined as the ratio
of lipid to total protein. WAT, white adipose tissue; Gastroc.,
gastrocnemius. *0.001 < p < 0.005. (n = 5 for each group.)374 Cell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inure 3C). In contrast, the ability of insulin to suppress
hepatic glucose output was similar in both Fyn null and
control mice, suggesting a primary effect on peripheral tis-
sue (Figure 3D). In line with this, insulin-induced Akt phos-
phorylation (Ser473 and Thr308) was increased in WAT of
the Fyn null mice compared to their controls (Figures 3E
and 3F). Together, these data establish that loss of Fyn
protein results in increased whole-body insulin sensitivity
from both improved skeletal muscle and adipose tissue
glucose disposal.
Fatty Acid Oxidation Is Markedly Enhanced
in Fyn Null Mice
Glucose utilization and fatty acid metabolism are highly in-
terrelated processes, as under normal physiological con-
ditions, glucose utilization causes an inhibition of fatty acid
metabolism. On the other hand, improved fatty acid oxida-
tion or fatty acid storage away from peripheral tissues
(liver andmuscle) results in increased glucosemetabolism
and insulin sensitivity (Krebs and Roden, 2005; Yu and
Ginsberg, 2005). Therefore, to determine the metabolic
phenotype of the Fyn null mice, we assessed the basal
metabolic rate (BMR), energy expenditure (EE), and respi-
ratory quotient (RQ) in control and Fyn null mice fed ad
libitum in dark (food intake, ‘‘fed’’) and light (reduced
food intake, ‘‘fasted’’) periods. In the basal state (light
cycle), the Fyn null mice displayed increased BMR as indi-
cated by elevated VO2 (Figure 4A). Consistent with an in-
creased metabolic rate, the Fyn null mice tended to have
a higher core body temperature after overnight fastingFigure 3. Fyn Null Mice Show Increased
Adipose and Skeletal Muscle Insulin
Sensitivity
Following an overnight fast, wild-type (WT) and
Fyn null (Fyn/) mice were subjected to a con-
scious euglycemic-hyperinsulinemic clamp.
(A) Whole-body glucose infusion rate.
(B) Insulin-stimulated glucose uptake in skele-
tal muscle (gastrocnemius).
(C) Insulin-stimulated glucose uptake in WAT.
(D) Hepatic glucose production in the basal
and the insulin-stimulated state. (n = 4 for Fyn
null; n = 3 for WT.)
(E and F) WAT explants from WT and Fyn null
mice either were left unstimulated or were in-
cubated with 10 nM insulin for 20 min. Cell
extracts were then prepared and immuno-
blotted for phospho-Ser473-Akt (E) or phos-
pho-Thr308-Akt and total Akt (F) expression
levels. Akt phosphorylation was determined in
three independent experiments and quantified
by laser scanning densitometry.c.
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Fyn Null Mice Display Increased Lipid OxidationFigure 4. Fyn Null Mice Display Increased Skeletal Muscle and Adipose Tissue Fatty Acid Oxidation
Wild-type (WT) and Fyn null (Fyn/) mice were placed into metabolic cages, and VCO2 and VO2 were recorded during the light (fasting) and dark
(feeding) periods.
(A) VO2 recorded during the light (rest/fasting) period, representative of the basal metabolic rate.
(B) Respiratory quotient from the average of eight Fyn null and eight wild-type mice fed a chow diet ad libitum.
(C) Energy expenditure was determined using the equation EE (Kcal/hr) = (3.941 3 VO2) + (1.106 3 VCO2).
(D and E) Palmitate uptake (D) and palmitate oxidation (E) in isolated tissues from Fyn null (n = 5) and wild-type (n = 4) mice.(data not shown). RQ was decreased and EE was in-
creased in the Fyn null mice without any changes in activ-
ity (Figures 4B and 4C). During the fed state (dark), RQ for
control mice was approximately 0.98, indicating a high
rate of carbohydrate metabolism and low whole-body
fatty acid oxidation (Figure 4B, solid bars). Although RQ
for the Fyn null mice was somewhat reduced (0.95), it
was similar to the control mice, indicating that the Fyn
null mice have high rates of energy expenditure due to
the efficient oxidation of carbohydrates in the fed state.
Together, these data show that the decreased body
weight of Fyn null mice results from a general elevated en-
ergy expenditure and a drastic increase in fatty acid utili-
zation during the fasted state.
Increased whole-body fatty acid oxidation could result
from a global increase in oxidative capacity or from a tis-Csue-specific increase. To examine the individual tissue
contributions, palmitate uptake and oxidation were deter-
mined in isolated explants of liver, skeletal muscle, and
WAT from fasted mice. Palmitate uptake was increased
in all these tissues in Fyn null mice, but the effect was
greater in adipose tissue (2-fold) compared to skeletal
muscle (1.5-fold) (Figure 4D). The same pattern was
observed for palmitate oxidation; that is, the greatest
increase occurred in adipose tissue (4-fold), with an
2- to 2.5-fold increase in skeletal muscle and a relatively
small increase in the liver (Figure 4E). Taken together,
these data demonstrate that the loss of Fyn results in a
tissue (muscle and adipose tissue)-specific fatty acid
oxidation increase and are consistent with the Fyn null
mice displaying a low RQ value during the light (reduced
food intake) period.ell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc. 375
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Fyn Null Mice Display Increased Lipid OxidationFigure 5. Increased Expression of Mito-
chondrial Protein in Fyn Null Mice
Immunoblots of WAT (individual) (A), brown ad-
ipose tissue (BAT) (in duplicate) (B), skeletal
muscle (gastrocnemius, in duplicate) (C), and
liver (in duplicate) (D) extracts for cytochrome
c, porine, prohibitin, CPT-1M (adipose tissue
and skeletal muscle), CPT-1L (liver), complex
II (70 kDa subunit), complex IV (subunit I), and
complex I (39 kDa subunit). Akt (WAT, skeletal
muscle, and liver) and p115 (BAT) were used
for internal loading.Mitochondrial Oxidative Capacity Is Increased
in Fyn Null Mice
Increased fatty acid oxidation could result from an in-
crease in the cellular content of mitochondria and/or
from increased oxidative flux through allosteric regulation
(Chien et al., 2000; Rasmussen and Wolfe, 1999). To
determine whether there is a change in mitochondrial
number, we examined the expression of structural mito-
chondrial markers in WAT, brown adipose tissue (BAT),
skeletal muscle, and liver (Figures 5A–5D). Immunoblot-
ting of adipose tissue (white and brown) and skeletal mus-
cle extracts demonstrated increased levels of several
structural mitochondrial markers such as porine and pro-
hibitin as well as the electron transport chain proteins cy-
tochrome c and protein subunits of complexes I, II, and IV.
The rate-limiting enzyme required for fatty acid oxidation,
carnitine palmitoyltransferase (CPT-1M; CPT-1L in liver),
was also strongly increased in Fyn null WAT, BAT, and
skeletal muscle. In contrast, the expression of the cyto-
solic enzyme Akt, which is intimately involved in insulin
signaling, was unaffected. Consistent with their having
only a small effect in liver fatty acid uptake and oxidation,376 Cell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inthere was no significant difference between these mito-
chondrial markers in livers of Fyn null and control mice.
AMP-Dependent Protein Kinase Activity
Is Increased in Fyn Null Mice
Fatty acid oxidation is coordinately regulated by the con-
trol of CPT-1 activity (the rate-limiting step for acyl-CoA
transport) through the regulation of malonyl-CoA levels.
Malonyl-CoA is a potent allosteric inhibitor of CPT-1,
and thus, high levels of malonyl-CoA inhibit fatty acid ox-
idation, whereas low levels enhance mitochondrial fatty
acid oxidation (McGarry, 1995; McGarry and Brown,
1997). In turn, malonyl-CoA is produced from acetyl-CoA
by the enzyme acetyl-CoA carboxylase (ACC), which
functions as part of an integrative energy sensor being
phosphorylated and enzymatically inhibited by both pro-
tein kinase A (PKA) and AMP kinase (AMPK)-dependent
serine phosphorylation (Hardie et al., 2003).
Consistent with this known dynamic regulation of mito-
chondrial fatty acid oxidation, in the fasted state, WAT,
BAT, and skeletal muscle isolated from Fyn null mice dis-
played a persistent elevation of ACC phosphorylationc.
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Fyn Null Mice Display Increased Lipid OxidationFigure 6. Fyn Deficiency or Inhibition
Increases AMPK Activity and AMPK and
ACC Phosphorylation Levels
(A–D) Immunoblots (in duplicate) of WAT (A),
skeletal muscle (B), BAT (C), and liver (D)
extracts with phospho-Ser79-ACC, phospho-
Thr172-AMPK, and total AMPK and ACC
antibodies.
(E) AMPK activity in WAT and white gastrocne-
mius (muscle) of fasted control (WT) and Fyn
null (Fyn/) mice.
(F) Immunoblots of SU6656- and PP2-treated
3T3-L1 adipocytes for phospho-Thr172-
AMPK and total AMPK (a subunit) protein
levels.compared to control mice, with no significant change in
the total ACC protein content (Figures 6A–6C). As ex-
pected, there was no significant difference in either ACC
phosphorylation or protein levels between the livers of
the Fyn null and control mice (Figure 6D). Moreover, the
phosphorylation of the activating site of AMPK (a subunit
Thr172) was also increased in adipose tissue and skeletal
muscle from Fyn null mice compared to control mice, with
no significant difference in the liver (Figures 6A–6D). Since
AMPK is subject to multiple positive and negative regula-
tor events, we directly determined the activation state of
AMPK in WAT and skeletal muscle extracts from control
and Fyn null mice (Figure 6E). Adipose tissue extracts
from Fyn null mice displayed a small but significant in-
crease in AMPK activity (1.4-fold), whereas skeletal
muscle from Fyn null mice displayed an 3-fold increase
in AMPK activity compared to control mice.
Since the AMPK activation in the Fyn null animals could
have resulted from either a signaling pathway coupling
Fyn with AMPK or a developmental adaptive response
due to a chronic loss of Fyn function, we next examined
the effect of two Src-family kinase inhibitors on AMPK
phosphorylation. Incubation of fully differentiated cultured
3T3-L1 adipocytes for 2 hr with PP2 or SU6656 resulted in
a dose-dependent increase in AMPK a subunit (Thr172)
phosphorylation without any significant effect on totalCAMPK protein levels (Figure 6F). These data indicate that
the acute reduction of Src-family tyrosine activity is suffi-
cient to enhance AMPK activity, thereby supporting an
acute Fyn signaling pathway coupled with the enzymatic
metabolic pathways that regulate adipose tissue and
skeletal muscle fatty acid oxidation.
DISCUSSION
In general, the Src-family kinases are regulated by various
extracellular signals and, in turn, control various cell and
tissue functions including cell migration, proliferation,
and differentiation (Hunter and Cooper, 1985; Thomas
and Brugge, 1997). For example, Src null mice display en-
hanced osteoblast differentiation and bone formation
(Soriano et al., 1991), and Lyn null mice have hyperrespon-
sive B cells and increased Ig levels and autoimmunity
(DeFranco et al., 1998). In addition to these development
functions, several studies have indirectly implicated Src-
family kinases in mediating insulin action and metabolic
control. In particular, in cultured adipocytes, Fyn is local-
ized to lipid raft microdomains and may be responsible
for the insulin-stimulated tyrosine phosphorylation of
caveolin (Mastick and Saltiel, 1997). Moreover, Fyn asso-
ciates with the lipid raft-localized long-chain fatty acid
translocase CD36/FAT (Bull et al., 1994; Huang et al.,ell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc. 377
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Fyn Null Mice Display Increased Lipid Oxidation1991). Although indirect, these studies are highly sugges-
tive of a role for Src-family kinases, particularly Fyn, in the
regulation of integrative metabolic functions in vivo.
Although Fyn null mice have been available for several
years, there has not been an investigation of themetabolic
phenotype of this animal model. Our analysis demon-
strates that Fyn null mice display several remarkable prop-
erties that result in improved insulin sensitivity compared
to wild-type controls. Since it is well established that intra-
tissue lipid accumulation results in states of insulin resis-
tance (Biddinger and Kahn, 2006; Kelley et al., 2002;
Krssak and Roden, 2004), one possibility is that the
decreased intramyocellular triglycerides and fatty acids
contribute to the enhancement of insulin sensitivity. How-
ever, these mice also have reduced intrahepatocellular
lipids with no significant difference in the ability of insulin
to suppress glucose output. Considering that these mice
also have reduced adiposity due to decreased lipid stor-
age (small adipocyte cell size) with no change in adipocyte
cell number, the primary cause of the decrease in circulat-
ing and intratissue lipids is increased fatty acid utilization.
In this regard, the Fyn null mice display increased whole-
body fatty acid oxidation consistent with a specific in-
crease in skeletal muscle and adipose tissue, but not liver,
fatty acid oxidation. Interestingly, similar to control mice,
Fyn null mice undergo cycling between carbohydrate
and fatty acid oxidation when switched from the fed to
the fasted state. Since relatively normal carbohydrate me-
tabolism occurs in the fed state, the Fyn null mice display
normal anabolic properties. However, in the fasted state,
thesemice display enhanced skeletal muscle and adipose
tissue fatty acid oxidation resulting in a greater state of ca-
tabolism. The consequence of increased peripheral tissue
fatty oxidation in the fasted state combined with an overall
increase in energy expenditure likely accounts for the
improved lipid profiles, reduced adiposity, and enhanced
insulin sensitivity.
Although themolecular pathway (or pathways) that cou-
ples Fyn function to fatty acid oxidation is not known, Fyn
null mice have increased a subunit Thr172 (activation site)
phosphorylation of AMPK in skeletal muscle and adipose
tissue. In this regard, AMPK plays a central role as a met-
abolic sensor for tissue energy status (Corton et al., 1994).
ACC is a critical downstream target for AMPK that regu-
lates fatty acid oxidation through the production of
malonyl-CoA (Brownsey et al., 2006). High levels of
malonyl-CoA inhibit fatty acid transport into mitochondria
through inactivation of CPT-1 (McGarry, 1995; McGarry
and Brown, 1997). AMPK phosphorylation of ACC1 on
Ser79 and ACC2 on Ser218 inhibits ACC activity, thereby
lowering malonyl-CoA levels, limiting fatty acid synthesis,
and derepressing fatty acid oxidation (Hardie et al., 2003;
Kusunoki et al., 2006; Musi, 2006). Consistent with this
pathway, in the fasted state, Fyn null mice also display
increased ACC phosphorylation in skeletal muscle and
adipose tissue, but not in liver. Thus, the combination of
increased mitochondria in these peripheral tissues and
enhanced activity of AMPK in the fasted state results in
a marked increase in fatty acid oxidation. Together, these378 Cell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Incdata support a model in which Fyn signaling suppresses
or limits the extent of fatty acid oxidation in the fasted
state. Consequently, the loss of Fyn function allows in-
creased energy production from lipid stores in the fasted
state. In turn, the physiologic integrative response to these
changes in fatty acid oxidation improves metabolic lipid
profiles and insulin sensitivity.
As these changes in metabolism were a result of con-
ventional Fyn ablation, the current study cannot directly
discriminate between altered development and acute
modulation of fatty acid metabolic pathways. However,
acute treatment of cultured 3T3-L1 adipocytes with two
different Src-family inhibitors resulted in the phosphoryla-
tion of the activation site of AMPK (Figure 6F). These data
strongly suggest that Fyn activity, but not Fyn expression,
is coupled to an acute signaling pathway that represses
AMPK activation. However, these data do not exclude
a potential development effect or the possibility that other
tissues, in particular the central nervous system, may also
contribute to the overall metabolic phenotype in vivo.
Since skeletal muscle and adipose tissue display in-
creased mitochondrial marker expression, it is likely that
at least some component of this phenotype results from
a chronic loss of Fyn function. On the other hand, our
data also suggest that the enhancement of fatty acid oxi-
dation in the fasted state occurs in a cell-autonomous
manner. That is, isolated skeletal muscle and adipose ex-
plants maintained the higher rate of palmitate uptake and
oxidation ex vivo following in vivo fasting. The cell auton-
omy of at least some of these responses is further sup-
ported by the effect of the Src kinase inhibitors in cultured
3T3-L1 adipocytes.
In any case, the data presented here demonstrate that
Fyn-deficient mice display low levels of plasma and intra-
tissue triglycerides and fatty acids, reduced adiposity, and
markedly improved glucose tolerance due to increased
peripheral tissue insulin sensitivity. These metabolic prop-
erties result at least in part from a specific increase in skel-
etal muscle and adipose tissue fatty acid oxidation in the
fasted state due to increased activation of AMPK and in-
hibition of ACC activity. Importantly, this study establishes
a role for Fyn and/or its downstream pathways as possible
targets for the treatment of obesity, dyslipidemia, and/or
insulin resistance.
EXPERIMENTAL PROCEDURES
Mice
pp59fyn null mice and controls were obtained from The Jackson Labo-
ratory and housed in a facility equipped with a 12 hr light/dark cycle.
Mice were continuously inbred from 50/50 mixed SV129J and
C57BLK6/J founders for at least 24 generations at The Jackson Labo-
ratory. Specific Fyn control mice were also inbred from 50/50 mixed
SV129J and C57BLK6/J founders. Animals were fed ad libitum a stan-
dard chow diet (Research Diets) containing 67% (kcal) carbohydrate,
19% protein, and 14% fat. Age- and/or weight- and sex-matched
Fyn null and control mice were used at 14–18 weeks. In addition, litter-
mate controls from mating heterozygotes were used as internal con-
trols. All studies were approved by and performed in compliance
with the guidelines of the Stony Brook University Institutional Animal
Care and Use Committee..
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Mice were fasted for 16 hr and then injected intraperitoneally with
1 g/kg of D-glucose in isotonic saline. Blood (5–10 ml) was collected
from the tail prior to and 10, 20, 30, 45, 60, 90, 120, and 150 min after
injection. Glucose was measured using a Precision Q$I$D monitoring
system (MediSense, Abbott Laboratories). A similar protocol was
used for measuring the response of plasma insulin to the glucose
load, except that blood (50 ml) was collected at 0, 30, and 60 min after
injection for insulin determination.
Euglycemic-Hyperinsulinemic Clamp
Indwelling catheters were surgically inserted in the right jugular vein
4 days prior to performing the EU clamp analysis. Mice were fully
recovered from surgery as reflected by their reaching preoperative
weight. The mice were fasted overnight, and basal rates of whole-
body glucose turnover were assessed using a continuous infusion of
[3H]glucose for 2 hr prior to the start of the clamp. A 2 hr EU clamp
was then conducted with primed continuous infusion of human insulin
(2.5 mU/kg/min, Eli Lilly) to raise insulin to a physiological range. Blood
samples (20 ml) were collected every 10 min and centrifuged, and 10 ml
of plasma was analyzed by a glucose oxidase method on a Beckman
Glucose Analyzer 2 (Beckman Coulter) to measure glucose concentra-
tions. A 20% glucose solution was infused at variable rates to maintain
glucose at basal concentration (100 mg/dl). Insulin-stimulated whole-
body glucose metabolism was assessed with a continuous infusion
of [3H]glucose (0.1 mCi/minute, PerkinElmer Life and Analytical
Sciences, Inc.) throughout the clamp. All infusions were performed
using microdialysis pumps (Harvard Apparatus and CMA Micro-
dialysis). Forty-five minutes before the end of the clamp, 2-deoxy-
D-[1-14C]glucose was administrated as a bolus (10 mCi) to estimate
insulin-stimulated glucose uptake in individual tissues. Blood samples
(20 ml) were taken at 5–10 min intervals until the end of the clamp to
measure plasma glucose, plasma [3H]glucose, 3H2O, 2-deoxy-
D-[1-14C]glucose, and insulin. At the end of the clamp, animals were
euthanized with sodium pentobarbital, and tissues were taken and
stored at 80C until analysis.
Plasma concentrations of [3H]glucose, 2-deoxy-D-[1-14C]glucose,
and 3H2O were measured after deproteinization of plasma samples
with ZnSO4 and Ba(OH)2. Basal and insulin-stimulated whole-body
glucose turnover were determined as the ratio of the [3H]glucose infu-
sion rate to the specific activity of the plasma glucose. Hepatic glucose
production was determined by subtracting the steady-state glucose
infusion rate from the whole-body glucose turnover rate. Glucose up-
take in tissues was calculated as previously described (Kim et al.,
2004). Tissues samples were homogenized and an ion-exchange
column was used on the supernatants to separate the 2-deoxy-
D-[1-14C]glucose-6-phosphate from the 2-deoxy [1-14C]glucose.
Analysis of Plasma Parameters
Tail-vein blood (150 ml) was collected from fasted (16 hr) mice into
heparin capillaries, and plasma was immediately prepared. Triglycer-
ides were measured with a kit from Thermo Electron, free fatty acids
with a kit from Roche, and insulin with an ELISA kit from Mercodia.
Microcomputed Tomography
Mice were placed under deep anesthesia with 2% isoflurane for 45min
and were scanned in an in vivo microcomputed tomography (micro-
CT) scanner (VivaCT 40, SCANCO Medical) at an isometric resolution
of 76 microns. Noise was removed from the CT images using a Gauss-
ian filter. The volume of interest (voi) spanned the abdominal region
from the hip-femoral joint to a landmark at the distal end of the lungs.
(The lungs were excluded from the voi, as their density is similar to fat.)
Threshold algorithms were used to quantify fat and total tissue vol-
umeswithin the voi. Scanning a freshly harvested fat pad from a similar
mouse at identical scan settings identified the upper and lower thresh-
olds that separated adipose tissue from denser or less dense tissues
and fluids. Fat volume was presented as an absolute number (mm3)
as well as with total tissue volume (mm3/mm3) as a referent.CWhole-Body Indirect Calorimetry
Oxygen and CO2 consumption were simultaneously determined by an
Oxymax open-circuit indirect calorimetry system (eight-cage system)
(Columbus Instruments). Animals were allowed to acclimatize to the
chambers for 16 hr, and measurements were taken subsequently for
48 hr during the light cycle (fasting period) and the dark cycle (feeding
period). Data were analyzed as the average of 12 hr measurements
for eachmouse during either the light or dark cycle. Instrument settings
were as follows: gas flow rate = 0.6 l/min, sample flow rate = 0.5 l/min,
settle time = 120 s, measure time = 60 s.
Fatty Acid Oxidation and Uptake in Isolated Organs
Overnight-fasted mice were anesthetized with isoflurane, and soleus
(red muscle), gastrocnemius (white muscle), liver, and adipose tissue
were quickly removed, rinsed in ice-cold saline, and preincubated
for 20min in oxygenated (95%O2, 5%CO2) KHB buffer supplemented
with 5 mM D-glucose and 2% BSA. Tissues were then incubated in
the same buffer containing 0.2 mM palmitate and 0.45 mCi/ml
[1-14C]palmitate (Amersham) bound to 2% BSA. Incubations were
carried out at 30C in glass vials (Kontes) under an atmosphere of
95%O2/5%CO2. At the end of the incubation, themediumwas quickly
transferred into vials equipped with a center well filled with 200 ml of
ethanolamine/ethylene glycol (1:2 vol/vol) (CO2 trapping agent).
Perchloric acid was added through the cap to a concentration of
0.6 mM, and the vials were incubated for 6 hr at 30C with moderate
shaking. The 14CO2 producedwas determined by scintillation counting
of the ethanolamine/ethylene glycol mixture.
Fatty acid uptake was performed using [9,10(n)-3H]palmitic acid.
Isolated tissues were preincubated as described above for 20 min
and then incubated in KHB buffer with 0.2 mM palmitate and
0.5 mCi/ml [9,10(n)-3H]palmitic acid bound to 2% BSA for 30 min.
Following this incubation, muscles were quickly blotted on filter paper
and frozen in liquid nitrogen. Muscles and adipose tissue were
digested for 1 hr at 50C in KOH (1M) and then counted for radioactive
tracer incorporation.
Tissue Embedding
Mice were anesthetized with isoflurane, and tissues were quickly re-
moved, rinsed in ice-cold PBS, and incubated overnight in formalin.
Adipose tissue was then washed with PBS for 15 min and dehydrated
by successive incubation in 70% to 100% ethanol solutions. Tissues
were embedded in paraffin, and slices were cut every 7mm. Hematox-
ylin and eosin staining was performed on tissues after rehydration, and
pictures were taken with a Nikon E990 camera mounted on an optical
microscope.
Western Blot Analysis
Fasted mice were anesthetized with isoflurane, and tissues were
rapidly removed, rinsed in ice-cold saline, freeze-clamped in liquid
nitrogen, and stored at 80C. For AMPK and phospho-AMPK immu-
noblotting, tissues were kept in liquid nitrogen until the day of analysis.
Tissues were ground into liquid nitrogen and homogenized in buffer
containing 50 mM Tris (pH 7.4), 1% glycerol, and 1% Triton X-100
supplemented with protease inhibitor (Complete Mini, Roche).
Homogenates were centrifuged for 30 min at 14,000 rpm at 4C, and
supernatants were collected. Protein concentration was determined
with a Bio-Rad assay.
The protein samples (20–30 mg) were separated on 8% or 10%
reducing polyacrylamide gels and electroblotted onto Immobilon-P
polyvinylidene difluoride membranes. Immunoblots were blocked
with 3% BSA in Tris-buffered saline for 60 min at room temperature
and then incubated overnight at 4C with indicated antibodies (Cell
Signaling, Upstate, and Alpha Diagnostic International) in Tris-buffered
saline and 0.05% Tween 20 (TBST) containing 0.1% BSA. Total and
phospho-ACC antibody was from Cell Signaling and recognized
both ACC1 and ACC2 isoforms. Blots were washed in TBST and incu-
bated with horseradish peroxidase-conjugated secondary antibodies
(1:30,000) for 30 min at room temperature. Membranes were washedell Metabolism 5, 371–381, May 2007 ª2007 Elsevier Inc. 379
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minescence using an ECL kit (Pierce).
Treatment of 3T3-L1 Adipocytes with Src-Family
Kinase Inhibitors
Murine 3T3-L1 preadipocytes were cultured and differentiated as de-
scribed in Watson and Pessin (2000). Fully differentiated adipocytes
were treated for 2 hr with the generic Src-family kinase inhibitors
PP2 or SU6656 (Calbiochem). Total lysates were prepared in buffer
containing 50 mM Tris (pH 7.4), 1% glycerol, and 1% Triton X-100
supplemented with protease inhibitor (Complete Mini, Roche).
Homogenates were centrifuged for 30 min at 14,000 rpm at 4C, and
supernatants were collected. Protein concentration was determined
with a Bio-Rad assay. Proteins (40 mg) were separated on 10% SDS-
polyacrylamide gels, and immunoblots were incubated with anti-
phospho-Thr172-AMPK or total AMPK antibodies.
AMP Kinase Activity in Adipose Tissue and Skeletal Muscle
AMPK activity was determined in WAT and white gastrocnemius of
fasted control and Fyn null mice. Animals were euthanized, and tissues
were rapidly removed and stored in liquid nitrogen. Tissues were ho-
mogenized in buffer containing 20 mM Tris (pH 7.5), 1 mM EDTA,
100 mM mannitol, 50 mM sodium fluoride, 5 mM sodium pyrophos-
phate, 1 mM DTT, 1 mM benzamidine, 0.04% trypsin inhibitor,
0.03% Pefabloc, 0.5% Triton X-100 and submitted to ultracentrifuga-
tion (48,000 3 g for 30 min). After extraction, 2–7 mg of supernatant
protein was assayed for AMPK activity by measuring incorporation
of 32P into a synthetic peptide (SAMS) as described in Winder and
Hardie (1996).
Statistics
Results are expressed as mean ± SEM. Differences between animals
and/or treatments were tested for statistical significance using
Student’s unpaired t test.
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